Evaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models

DocumentFichier
Fichier pdf chargé le 14/09/2018 à 11:54:48
Accès identifié
(version éditeur)
Request
TitreEvaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models
Type de publicationArticle de revue
AuteurBastiancich, Chiara
1, 2
, Lemaire, Laurent
1, 3
, Bianco, John , Franconi, Florence
1, 3
, Danhier, Fabienne , Préat, Véronique , Bastiat, Guillaume , Lagarce, Frédéric
1, 5
EditeurFuture Medicine
TypeArticle scientifique dans une revue à comité de lecture
Année2018
LangueAnglais
Date11 Sept. 2018
Numéro6
Pagination1999-2013
Volume13
Titre de la revueNanomedicine (Lond)
ISSN1748-6963
Mots-clésGlioblastoma, Hydrogel, Lipid nanocapsules, Local delivery, MRI, rat, resection
Résumé en anglais

AIM: Anticancer drug-loaded hydrogels are a promising strategy for the local treatment of incurable brain tumors such as glioblastoma (GBM). Recently, we demonstrated the efficacy of lauroyl-gemcitabine lipid nanocapsule hydrogel (GemC-LNC) in a U-87 MG xenograft orthotopic mouse model. In this study, we developed a reliable and reproducible surgical procedure to resect orthotopic GBM tumors in rats. GemC-LNC hydrogel integrity was tested after brain administration in rats and its anti-tumor efficacy was tested on a 9L syngeneic orthotopic model.

RESULTS: We demonstrated that LNC integrity is maintained at least for one week after local administration of GemC-LNC. GemC-LNC was able to delay the formation of recurrences in 9L tumor-bearing resected rats, demonstrating the efficacy of this nanomedicine hydrogel in this preclinical model.

CONCLUSION: Our results confirm that GemC-LNC, a hydrogel uniquely formed by a nanocarrier and a cytotoxic drug, could be a promising and safe delivery tool for the local treatment of operable GBM tumors.

URL de la noticehttp://okina.univ-angers.fr/publications/ua17540
DOI10.2217/nnm-2018-0057
Lien vers le document

https://www.futuremedicine.com/doi/10.2217/nnm-2018-0057

Autre titreNanomedicine (Lond)
Identifiant (ID) PubMed30204064